“Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography”
**SME INSTRUMENT**
*The SMEs “Champions League”*

**Phase 1**
- Concept & Feasibility Assessment

**Input:** "Business Plan 1" (~ 10 pages)
  - Feasibility of concept
  - Risk Assessment
  - IP regime
  - Partner Search
  - Design Study

*Lump sum: ~ 50,000 €
≈ 6 months*

**Phase 2**
- R&D, Demonstration, Market Replication

**Input:** "Business Plan 2" + description of activities Phase 2 (~ 30 pages)
  - Development, prototype, test
  - Miniaturization/design
  - Clinical trials

*1 to 2,5 mn €
12-24 months*

**Phase 3**
- Commercialization

**Input:** Promotion of idea
  - Facilitate access to private finance
  - Support by means of networking, trainings, knowledge sharing, and dissemination

No Funding

www.gliomark.eu
Clinical research for the validation of biomarkers and/or diagnostic medical devices (Phase 1)

Horizon 2020
Call: H2020-SMEINST-1-2014
Topic: PHC-12-2014-1
Type of action: SME-1
Proposal number: SEP-210176060
Proposal acronym: BIOPHOS

www.gliomark.eu
Based on the evaluation results, we regret to inform you that the Agency has decided that no financial contribution could be made for your proposal. The decision was motivated by the following:

The score obtained by your proposal does not reach the minimum threshold.

We recognise the effort you have put into submitting an application for a H2020 SME Phase 1 funding. If you want to improve your application and are considering re-submitting, we recommend that you contact an adviser from the EEN network (http://een.ec.europa.eu/). We hope that despite the disappointing result, you will find other ways of carrying out the business ideas reflected in your proposal.
# Proposal Evaluation Form

## Evaluation Summary Report

**Evaluation Result**

Total score: **7.61** (Threshold: **13.00**)

### Criterion 1 - Impact

Score: **3.00** (Threshold: 4.00/5.00, Weight: 100.00%)

Good. The proposal addresses the criterion well, although improvements would be necessary.

### Criterion 2 - Excellence

Score: **2.66** (Threshold: 4.00/5.00, Weight: 100.00%)

Fair to good. While the proposal broadly addresses the criterion, there are some weaknesses.

### Criterion 3 - Quality and efficiency of implementation

Score: **1.95** (Threshold: 4.00/5.00, Weight: 100.00%)

Poor. The criterion is addressed in an inadequate manner, or there are serious inherent weaknesses.
Clinical research for the validation of biomarkers and/or diagnostic medical devices (Phase 2)

| European Commission - Research - Participants |
| Proposal Submission Forms |

Horizon 2020

Call: H2020-SMEINST-2-2014

Topic: PHC-12-2014

Type of action: SME-2

Proposal number: SEP-210225391

Proposal acronym: GLIOMARK
EUROPEAN COMMISSION
Executive Agency for Small and Medium-sized Enterprises (EASME)
Unit A2
Head of Unit

Brussels,

Alex STRONGILOS
PRO-ACTINA
ANONIMI ET AIKIDOU
ARCHIMIDIOU
194 00 ATHINA
Greece

Subject: Result of Evaluation of proposals / Invitation to grant preparation
Programme/Call: H2020 — H2020-SMEINST-2-2014
Proposal: 673737 — GLIOMARK

Dear Alex STRONGILOS,

We are pleased to inform you that the aforementioned proposal has been favourably evaluated by the Agency. Consequently, we wish to proceed to the preparation of the Grant Agreement based on your proposal.
**Proposal Evaluation Form**

**EUROPEAN COMMISSION**
Horizon 2020 - Research and Innovation Framework Programme

**Evaluation Summary Report**

**Call:** H2020-SMEINST-2-2014_17-12-2014  
**Funding scheme:** SME instrument phase 2  
**Proposal number:** 673737  
**Proposal acronym:** GLIOMARK  
**Duration (months):** 48  
**Proposal title:** Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography  
**Activity:** PHC-12-2014

---

**Evaluation Summary Report**

**Evaluation Result**

**Total score:** 13.02 (Threshold: 12.00)

**Criterion 1 - Impact**

Score: **4.36** (Threshold: 4.00/5.00, Weight: 100.00%)  

**Criterion 2 - Excellence**

Score: **4.44** (Threshold: 3.00/5.00, Weight: 100.00%)  

**Criterion 3 - Quality and efficiency of implementation**

Score: **4.22** (Threshold: 3.00/5.00, Weight: 100.00%)
**Keys to success:**

1. **Excellent & Innovative idea**
2. **Selection of partners**
3. **Solid Strategy**
4. **Impact**
   - Company
   - Country
   - European Union (patients, healthcare system, doctors)
5. **Implementation**
6. **Commercialization plan / Competition**
7. **Securing Intellectual property / Freedom to operate**
8. **Dissemination of knowledge**

**EU’s Main Evaluation Criteria:**
- **Excellence in Innovation**
- **Economic & social impact**
- **Implementation**

www.gliomark.eu
WP9 Management & administration

WP1 Regulatory

WP2 Prep phase II

WP3 Conduct phase II

WP4 Analyse phase II

WP5 Prep phase III

WP6 Conduct phase III

WP7 Analyse & publish phase II

WP8 GMP Manufacturing

WP10 Exploitation & communication

www.gliomark.eu
Congratulations, you are among the 6% of successful proposals under the European Commission's SME Instrument funding programme. Your project is highly important to
Horizon 2020 SME Instrument beneficiaries

Last update: 07/09/2015

Phase 1 | Phase 2


www.gliomark.eu
Thank You!